TLT's valuation 44x lower than BioNtech 3.4G$US 2019 IPOThe link below just shows how TLT's valuation is low when compared to the one of BioNtech, not at its peak but rather at its IPO valuation (lowest ever valuation).
Market capitalization of BioNTech (BNTX) With a current valuation of 76MM$US,
TLT's valuation is 44x lower than the 3.4G$US one given to BioNtech, when this latest was IPOed!
At IPO, in Oct. 2019,
way before COVID-19 arrived and 15 months after its
425M$US jv with Pfizer regarding an
influenza vaccine collaboration, BioNtech was valued at
3.4G$US, the biggest IPO in biotechs history, thanks to the promising attributes, but then yet to be tested in humans, of its mRNA platform.
TLT's technology is on the verge of possibly:
- becoming the next SOC against NMIBC (BCG-unresponsive)
- launching Rutherrin against NSCLC and GBM (Ph. 1b yet to be launched though)
- having an anti-virus platform (proof-of-concept with the High Containment Respiratory Virus Group, Special Pathogens, PHAC with rapid destruction of various viruses, including: H1N1 Influenza, Zika and a Biological Safety Level (“BSL”)-2 coronavirus at low nanomolar (“nM”) concentrations.)
BioNtech's technology for the oncology market has never been tested yet and couldn't match TLT's anti-cancer technology. But has been stellar in the anti-virus arena.